已收盘 02-06 16:00:00 美东时间
+0.640
+8.63%
W.W. Grainger Inc. veröffentlicht Transkript zur Q4 2025 Earnings Call W.W. Grainger Inc. hat das Transkript seines Q4 2025 Earnings Calls veröffentlicht. Bei dem Ereignis am 3. Februar 2026 nahmen unter anderem der Chairman & CEO des Unternehmens teil. Im Mittelpunkt des Gesprächs standen die Bewäl
02-03 21:04
Personalis Study Shows Ultrasensitive ctDNA Test Predicts Immunotherapy Response Across Multiple Cancers Personalis Inc. has announced the publication of new clinical study results highlighting the performance of its NeXT Personal® assay for ultrasensitive monitoring of molecular residual disease (M
02-02 19:00
今日重点评级关注:Oppenheimer:维持Pelthos Therapeutics"跑赢大市"评级,目标价从57美元升至60美元;Small Cap Consumer Research:维持Lands' End"买入"评级,目标价从20美元升至45美元
01-27 10:02
9 analysts have shared their evaluations of Personalis (NASDAQ:PSNL) during the...
01-27 04:01
Guggenheim analyst Subbu Nambi maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price target from $12 to $13.
01-27 00:38
Personalis CFO and COO Aaron Tachibana Reports Disposal of Common Shares Aaron Tachibana, Chief Financial Officer and Chief Operating Officer of Personalis Inc., reported a disposal of common shares of Personalis Inc. The full filing can be accessed through the link below. Disclaimer: This news brie
01-24 07:03
Cathie Wood’s ARK Invest (ARKK) deepened investment in AI chipmakers, gene-editing companies, and autonomous-driving developers while continuing to trim positions in Tesla (TSLA) and several mature te...
01-19 20:35
New NeXT Personal® extension empowers clinicians to identify emerging resistance and therapeutically targetable mutations during disease monitoring and surveillance
01-13 05:02
Cathie Wood’s ARK Invest repositions toward long-term innovation themes like advanced air mobility, autonomous transport, and gene editing during the last week, while reducing exposure to more matur...
01-12 20:30
今日重点评级关注:Needham:维持Cartesian Therapeutics"买入"评级,目标价从40美元升至42美元;Piper Sandler:维持Acrivon Therapeutics"超配"评级,目标价从6美元升至8美元
01-12 14:09